

UDK 37

ISSN 2545 – 4439

ISSN 1857 - 923X

INTERNATIONAL JOURNAL

Institute of Knowledge Management

KNOWLEDGE



Scientific Papers

Vol. 55.4

MEDICAL SCIENCES AND HEALTH

KIJ

Vol.

55

No. 4

pp. 497 - 848

Skopje, 2022

KNOWLEDGE



INTERNATIONAL JOURNAL

**SCIENTIFIC PAPERS
VOL. 55.4**

December, 2022

**INSTITUTE OF KNOWLEDGE MANAGEMENT
SKOPJE**



KNOWLEDGE
International Journal Scientific Papers Vol. 55.4

ADVISORY BOARD

Vlado Kambovski PhD, Robert Dimitrovski PhD, Siniša Zarić PhD, Maria Kavdanska PhD, Mirjana Borota – Popovska PhD, Veselin Videv PhD, Ivo Zupanovic, PhD, Savo Ashtalkoski PhD, Zivota Radosavljević PhD, Laste Spasovski PhD, Mersad Mujevic PhD, Milka Zdravkovska PhD, Drago Cvijanovic PhD, Predrag Trajković PhD, Lazar Stosic PhD, Krasimira Staneva PhD, Nebojsa Pavlović PhD, Daniela Todorova PhD, Baki Koleci PhD, Lisen Bashkurti PhD, Zoran Srzentić PhD, Itska Derijan PhD, Sinisa Opic PhD, Marija Kostic PhD

Print: GRAFOPROM – Bitola

Editor: IKM – Skopje

Editor in chief

Robert Dimitrovski, PhD

KNOWLEDGE - International Journal Scientific Papers Vol. 55.4

ISSN 1857-923X (for e-version)

ISSN 2545 – 4439 (for printed version)

INTERNATIONAL EDITORIAL BOARD

President: Academic Prof. Vlado Kambovski PhD, Skopje (N. Macedonia)

Vice presidents:

Prof. Robert Dimitrovski PhD, Institute of Knowledge Management, Skopje (N. Macedonia)

Prof. Sinisa Zaric, PhD, Faculty of Economics, University of Belgrade, Belgrade (Serbia)

Prof. Mersad Mujevic PhD, Public Procurement Administration of Montenegro (Montenegro)

Prof. Tihomir Domazet PhD, President of the Croatian Institute for Finance and Accounting, Zagreb (Croatia)

Members:

- Prof. Azra Adjajlic – Dedovic PhD, Faculty of criminology and security, Sarajevo (Bosnia & Herzegovina)
- Prof. Aleksandar Korablev PhD, Faculty of economy and management, Saint Petersburg State Forest Technical University, Saint Petersburg (Russian Federation)
- Prof. Anita Trajkovska PhD, Rochester University (USA)
- Prof. Aziz Pollozhani PhD, Rector, University Mother Teresa, Skopje (N.Macedonia)
- Prof. Anka Trajkovska-Petkoska PhD, UKLO, Faculty of technology and technical sciences, Bitola (N. Macedonia)
- Prof. Aneta Mijoska PhD, Faculty of Dentistry, University “St. Cyril and Methodius”, Skopje (N. Macedonia)
- Prof. Alisabri Sabani PhD, Faculty of criminology and security, Sarajevo (Bosnia & Herzegovina)
- Prof. Artan Nimani PhD, Rector, University of Gjakova “Fehmi Agani” (Kosovo)
- Prof. Ahmad Zakeri PhD, University of Wolverhampton, (United Kingdom)
- Prof. Ana Dzumalieva PhD, South-West University “Neofit Rilski”, Blagoevgrad (Bulgaria)
- Prof. Ali Hajro, PhD, Military Academy “Mihailo Apostolski”, Skopje (N. Macedonia)
- Prof. Branko Sotirov PhD, University of Rousse, Rousse (Bulgaria)
- Prof. Branko Boshkovic, PhD, College of Sports and Health, Belgrade (Serbia)
- Prof. Branimir Kampl PhD, Institute SANO, Zagreb (Croatia)
- Prof. Baki Koleci PhD, University Hadzi Zeka, Peja (Kosovo)
- Prof. Branislav Simonovic PhD, Faculty of Law, Kragujevac (Serbia)
- Prof. Bistra Angelovska, Faculty of Medicine, University “Goce Delcev”, Shtip (N.Macedonia)
- Prof. Cezar Birzea, PhD, National School for Political and Administrative Studies, Bucharest (Romania)
- Prof. Cvetko Andreevski, Faculty of Tourism, UKLO, Bitola (N.Macedonia)
- Prof. Drago Cvijanovic, PhD, Faculty of Hotel Management and Tourism, University of Kragujevac, Vrnjacka Banja (Serbia)
- Prof. Dusan Ristic, PhD Emeritus, College of professional studies in Management and Business Communication, Novi Sad (Serbia)
- Prof. Darijo Jerkovic PhD, Faculty of Business Economy, University “Vitez”, (Bosnia & Herzegovina)
- Prof. Daniela Todorova PhD, “Todor Kableshev” University of Transport, Sofia (Bulgaria)
- Prof. Dragan Kokovic PhD, University of Novi Sad, Novi Sad (Serbia)
- Prof. Dragan Marinkovic PhD, High health – sanitary school for professional studies, Belgrade (Serbia)
- Prof. Itska Mihaylova Derijan PhD, University Neofit Rilski, Faculty of pedagogy, Blagoevgrad (Bulgaria)

- Prof. Dzulijana Tomovska, PhD, Faculty of Biotechnical sciences, Bitola (N.Macedonia)
- Prof. Evgenia Penkova-Pantaleeva PhD, UNWE -Sofia (Bulgaria)
- Prof. Fadil Millaku, PhD, University “Hadzi Zeka”, Peja (Kosovo)
- Prof. Fatos Ukaj, University “Hasan Prishtina”, Prishtina (Kosovo)
- Prof. Georgi Georgiev PhD, National Military University “Vasil Levski”, Veliko Trnovo (Bulgaria)
- Prof. Halit Shabani, PhD, University “Hadzi Zeka”, Peja (Kosovo)
- Prof. Halima Sofradzija, PhD, University of Sarajevo, Sarajevo (Bosnia and Herzegovina)
- Prof. Haris Halilovic, Faculty of criminology and security, University of Sarajevo, Sarajevo (Bosnia and Herzegovina)
- Prof. Helmut Shramke PhD, former Head of the University of Vienna Reform Group (Austria)
- Prof. Hristina Georgieva Yancheva, PhD, Agricultural University, Plovdiv (Bulgaria)
- Prof. Hristo Beloev PhD, Bulgarian Academy of Science, Rector of the University of Rousse (Bulgaria)
- Prof. Hristina Milcheva, Medical college, Trakia University, Stara Zagora (Bulgaria)
- Prof. Izet Zeqiri, PhD, Academic, SEEU, Tetovo (N.Macedonia)
- Prof. Ivan Marchevski, PhD, D.A. Tsenov Academy of Economics, Svishtov (Bulgaria)
- Prof. Ibrahim Obhodjas PhD, Faculty of Business Economy, University “Vitez”, (Bosnia & Herzegovina)
- Doc. Igor Stubelj, PhD, Faculty of Management, Primorska University, Koper (Slovenia)
- Prof. Ivo Zupanovic, PhD, Faculty of Business and Tourism, Budva (Montenegro)
- Prof. Ivan Blazhevski, PhD, Institute for Sociological, Political and Juridical Research, Skopje (N.Macedonia)
- Prof. Isa Spahiu PhD, AAB University, Prishtina (Kosovo)
- Prof. Ivana Jelik PhD, University of Podgorica, Faculty of Law, Podgorica (Montenegro)
- Prof. Islam Hasani PhD, Kingston University (Bahrein)
- Prof. Jamila Jaganjac PhD, Faculty of Business Economy, University “Vitez”, (Bosnia & Herzegovina)
- Prof. Jova Ateljevic PhD, Faculty of Economy, University of Banja Luka, (Bosnia & Herzegovina)
- Prof. Jonko Kunchev PhD, University „Cernorizec Hrabar“ - Varna (Bulgaria)
- Prof Karl Schopf, PhD, Akademie fur wissenschaftliche forchung und studium, Wien (Austria)
- Prof. Katerina Belichovska, PhD, Faculty of Agricultural Sciences, UKIM, Skopje (N. Macedonia)
- Prof. Krasimir Petkov, PhD, National Sports Academy “Vassil Levski”, Sofia (Bulgaria)
- Prof. Kamal Al-Nakib PhD, College of Business Administration Department, Kingdom University (Bahrain)
- Prof. Kiril Lisichkov, Faculty of Technology and Metallurgy, UKIM, Skopje (N.Macedonia)
- Prof. Krasimira Staneva PhD, University of Forestry, Sofia (Bulgaria)
- Prof. Lidija Tozi PhD, Faculty of Pharmacy, Ss. Cyril and Methodius University, Skopje (N.Macedonia)
- Prof. Laste Spasovski PhD, Vocational and educational centre, Skopje (N.Macedonia)
- Prof. Larisa Velic, PhD, Faculty of Law, University of Zenica, Zenica (Bosnia and Herzegovina)
- Prof. Łukasz Tomczyk PhD, Pedagogical University of Cracow (Poland)
- Prof. Lujza Grueva, PhD, Faculty of Medical Sciences, UKIM, Skopje (N.Macedonia)

- Prof. Lazar Stosic, PhD, Association for development of science, engineering and education, Vranje (Serbia)
- Prof. Lulzim Zeneli PhD, University of Gjakova “Fehmi Agani” (Kosovo)
- Prof. Lisen Bashkurti PhD, Global Vice President of Sun Moon University (Albania)
- Prof. Lence Mircevaska PhD, High Medicine School, Bitola, (N.Macedonia)
- Prof. Ljupce Kocovski PhD, Faculty of Biotechnical sciences, Bitola (N.Macedonia)
- Prof. Marusya Lyubcheva PhD, University “Prof. Asen Zlatarov”, Member of the European Parliament, Burgas (Bulgaria)
- Prof. Marija Magdinceva – Shopova PhD, Faculty of tourism and business logistics, University “Goce Delchev”, Shtip (N. Macedonia)
- Prof. Maria Kavdanska PhD, Faculty of Pedagogy, South-West University Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Vaska Stancheva-Popkostadinova, PhD, Faculty of Public Health and Sport, SWU Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Mirjana Borota-Popovska, PhD, Centre for Management and Human Resource Development, Institute for Sociological, Political and Juridical Research, Skopje (N.Macedonia)
- Prof. Mihail Garevski, PhD, Institute of Earthquake Engineering and Engineering Seismology, Skopje (N.Macedonia)
- Prof. Misho Hristovski PhD, Faculty of Veterinary Medicine, Ss. Cyril and Methodius University, Skopje (N.Macedonia)
- Prof. Mitko Kotovchevski, PhD, Faculty of Philosophy, UKIM, Skopje (N.Macedonia)
- Prof. Milan Radosavljevic PhD, Dean, Faculty of strategic and operational management, Union University, Belgrade (Serbia)
- Prof. Marija Topuzovska-Latkovikj, PhD, Centre for Management and Human Resource Development, Institute for Sociological, Political and Juridical Research, Skopje (N.Macedonia)
- Prof. Marija Knezevic PhD, Academic, Banja Luka, (Bosnia and Herzegovina)
- Prof. Margarita Bogdanova PhD, D.A.Tsenov Academy of Economics, Svishtov (Bulgaria)
- Prof. Mahmut Chelik PhD, Faculty of Philology, University “Goce Delchev”, Shtip (N.Macedonia)
- Prof. Mihajlo Petrovski, PhD, Faculty of Medical Sciences, University “Goce Delchev”, Shtip (N.Macedonia)
- Prof. Marija Mandaric PhD, Faculty of Hotel Management and Tourism, University of Kragujevac, Vrnjacka Banja (Serbia)
- Prof. Marina Simin PhD, College of professional studies in Management and Business Communication, Sremski Karlovci (Serbia)
- Prof. Miladin Kalinic, College of professional studies in Management and Business Communication, Sremski Karlovci (Serbia)
- Prof. Marijan Tanushevski PhD, Macedonian Scientific Society, Bitola (N. Macedonia)
- Prof. Mitre Stojanovski PhD, Faculty of Biotechnical sciences, Bitola (N.Macedonia)
- Prof. Miodrag Smelcerovic PhD, High Technological and Artistic Vocational School, Leskovac (Serbia)
- Prof. Nadka Kostadinova, Faculty of Economics, Trakia University, Stara Zagora (Bulgaria)
- Prof. Natalija Kirejenko PhD, Faculty For economic and Business, Institute of Entrepreneurial Activity, Minsk (Belarus)
- Prof. Nenad Taneski PhD, Military Academy “Mihailo Apostolski”, Skopje (N.Macedonia)
- Prof. Nevenka Tatkovic PhD, Juraj Dobrila University of Pula, Pula (Croatia)
- Prof. Nedžad Korajlic PhD, Faculty of criminal justice and security, University of Sarajevo (Bosnia and Herzegovina)
- Prof. Nikola Sabev, PhD, Angel Kanchev University of Ruse, Ruse (Bulgaria)

- Prof. Nonka Mateva PhD, Medical University, Plovdiv (Bulgaria)
- Prof. Nikolay Georgiev PhD, “Todor Kableshkov” University of Transport, Sofia (Bulgaria)
- Prof. Nishad M. Navaz PhD, Kingdom University (India)
- Prof. Nano Ruzhin PhD, Faculty of Law, AUE-FON University, Skopje (N.Macedonia)
- Prof. Oliver Dimitrijevic PhD, High medicine school for professional studies “Hipokrat”, Bujanovac (Serbia)
- Prof. Paul Sergius Koku, PhD, Florida State University, Florida (USA)
- Prof. Primoz Dolenc, PhD, Faculty of Management, Primorska University, Koper (Slovenia)
- Prof. Petar Kolev PhD, “Todor Kableshkov” University of Transport, Sofia (Bulgaria)
- Prof. Pere Tumbas PhD, Faculty of Economics, University of Novi Sad, Subotica (Serbia)
- Prof. Rade Ratkovic PhD, Faculty of Business and Tourism, Budva (Montenegro)
- Prof. Rositsa Chobanova PhD, University of Telecommunications and Posts, Sofia (Bulgaria)
- Prof. Rossana Piccolo PhD, Università degli studi della Campania - Luigi Vanvitelli (Italy)
- Prof. Rumen Valcovski PhD, Imunolab Sofia (Bulgaria)
- Prof. Rumen Stefanov PhD, Faculty of public health, Medical University of Plovdiv (Bulgaria)
- Prof. Rumen Tomov PhD, University of Forestry, Sofia (Bulgaria)
- Prof. Sasho Korunoski PhD, UKLO, Bitola (N.Macedonia)
- Prof. Snezhana Lazarevic, PhD, College of Sports and Health, Belgrade (Serbia)
- Prof. Vasil Markov PhD, Faculty of Arts, SWU Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Stojna Ristevska PhD, High Medicine School, Bitola, (N. Macedonia)
- Prof. Suzana Pavlovic PhD, High health – sanitary school for professional studies, Belgrade (Serbia)
- Prof. Sandra Zivanovic, PhD, Faculty of Hotel Management and Tourism, University of Kragujevac, Vrnjacka Banja (Serbia)
- Prof. Shyqeri Kabashi, College “Biznesi”, Prishtina (Kosovo)
- Prof. Temelko Risteski PhD, Faculty of Law, AUE-FON University, Skopje (N. Macedonia)
- Prof. Todor Krystevich, D.A. Tsenov Academy of Economics, Svishtov (Bulgaria)
- Prof. Todorcka Atanasova, Faculty of Economics, Trakia University, Stara Zagora (Bulgaria)
- Prof. Tzako Pantaleev PhD, NBUniversity, Sofia (Bulgaria)
- Prof. Vojislav Babic PhD, Institute of Sociology, University of Belgrade (Serbia)
- Prof. Volodymyr Denysyuk, PhD, Dobrov Center for Scientific and Technological Potential and History studies at the National Academy of Sciences of Ukraine (Ukraine)
- Prof. Valentina Staneva PhD, “Todor Kableshkov” University of Transport, Sofia (Bulgaria)
- Prof. Venus Del Rosario PhD, Arab Open University (Philippines)
- Prof. Vjollca Dibra PhD, University of Gjakova “Fehmi Agani” (Kosovo)
- Prof. Yuri Doroshenko PhD, Dean, Faculty of Economics and Management, Belgorod (Russian Federation)
- Prof. Zlatko Pejkovski, PhD, Faculty of Agricultural Sciences, UKIM, Skopje (N.Macedonia)
- Prof. Zivota Radosavljevic PhD, Faculty FORCUP, Union University, Belgrade (Serbia)
- Prof. Zorka Jugovic PhD, High health – sanitary school for professional studies, Belgrade (Serbia)

REVIEW PROCEDURE AND REVIEW BOARD

Each paper is reviewed by the editor and, if it is judged suitable for this publication, it is then sent to two referees for double blind peer review.

The editorial review board is consisted of 67 members, full professors in the fields 1) Natural and mathematical sciences, 2) Technical and technological sciences, 3) Medical sciences and Health, 4) Biotechnical sciences, 5) Social sciences, and 6) Humanities from all the Balkan countries and the region.

CONTENTS

ASSOCIATION OF THE TREATMENT WITH 5 ALPHA-REDUCTASE INHIBITORS WITH THE PSYCHOLOGICAL WELL-BEING OF PATIENTS WITH BENIGN PROSTATE HYPERPLASIA .	515
Maja Sofronievska Glavinov	515
IMPACT OF SYMPTOM SEVERITY SCORE AND TYPE OF TREATMENT ON QUALITY OF LIFE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA	521
Maja Sofronievska Glavinov	521
Jovan Ivcev	521
Ivica Stojanoski	521
EARLY ERCP FOR SHORTER HOSPITALIZATION IN ACUTE BILIARY PANCREATITIS -CASE REPORT	527
Aleksandra Toneva Nikolova	527
Aleksandra Jordanova.....	527
Sasho Mihailov	527
TRANSARTERIAL CHEMOEMBOLIZATION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA -CASE REPORT	533
Ljenche Gjorgjieva Stojanov	533
Valentina Risteska Cvetkoska	533
QT PROLONGATION AND VENTRICULAR ARRHYTHMIA IN METHADONE USER PRESENTING WITH SEVERE HYPOKALEMIA	539
Irina Kotlar Velkova	539
Mario Jovanoski	539
Ivica Bojovski.....	539
Elena Grueva Nastevska	539
Hajber Taravari.....	539
Ana Celikic	539
Marjan Boshev.....	539
ASSESSMENT OF NEURO-MUSCULAR ACTIVITY DURING A SUBMAXIMAL LOAD ERGOMETRICAL TEST.....	545
Daniela Petkovska	545
IMPLEMENTING THE BRODY SCORING SYSTEM IN THE EVALUATION OF SEVERITY OF PULMONARY CHANGES IN CYSTIC FIBROSIS ON HIGH RESOLUTION COMPUTED TOMOGRAPHY	551
Sonja Nikolova	551
PULMONARY FUNCTION EXAMINATION IN PATIENTS AFTER SEVERE COVID-19 PNEUMONIA.....	557
Plamena Stoimenova	557
Stoilka Mandadzhieva	557
Blagoi Marinov.....	557
PRIMARY HEALTH CARE IN BULGARIA - REVIEW	563
Teodora Dimcheva	563
KNOWLEDGE OF ANALYTICAL PRINCIPLES IN LABORATORY HEMATOLOGY AND THEIR RELATION TO THE MOST COMMON ERRORS IN THE PRE-ANALYTICAL STAGE	571
Ivelina Dobreva	571
Pavlina Teneva	571
THYROID VOLUME IN HEALTHY PREGNANT WOMEN FROM PLOVDIV REGION	575
Boyan Delev	575
Tanya Deneva	575
Boyan Nonchev	575
Presiyana Nyagolova	575

Maria Miteva	575
HEALTH CARE FOR THE ELDERLY AND OLD PEOPLE DURING THE COVID PANDEMIC ...	581
Petya Krumova	581
Anushka Uzunova.....	581
PATHOGENESIS AS A MAIN FACTOR IN THE PRESENTATION AND INTERPRETATION OF THE ROENTGENOGRAM OF COVID 19 POSITIVE PATIENTS	587
Dragana Mogilevska Gruevska.....	587
Gordana Panova.....	587
EFFECT OF TOPIRAMATE TREATMENT ON PASSIVE COGNITIVE FUNCTIONS AND LOCOMOTOR ACTIVITY IN A MODEL OF DRUG-INDUCED AMNESIA	593
Michaela Shishmanova-Doseva	593
EFFECT OF LAMOTRIGINE TREATMENT ON ACTIVE AVOIDANCE PERFORMANCE IN A MODEL OF DIAZEPAM-INDUCED AMNESIA	599
Michaela Shishmanova-Doseva	599
INCIDENCE OF TUMOURS IN THE MAXILLOFACIAL REGION.....	605
Ivan Gerdzhikov	605
PROSTHETIC APPROACH OF DENTAL EROSION IN PATIENT WITH GASTROESOPHAGEAL REFLUX DISEASE - CASE REPORT.....	613
Natasha Stavreva	613
Natasha Tosheska Spasova.....	613
TRAUMATIC DENTAL INJURIES IN THE PRIMARY DENTITION.....	617
Sanja Nashkova	617
ADULT ORTHODONTICS.....	623
Natasha Toseska-Spasova.....	623
Natasha Stavreva	623
Biljana Dzipunova.....	623
TYPES OF CLASSIFICATIONS OF MAXILLARY DEFECTS	629
Ivan Gerdzhikov	629
CORRELATION OF THE POST-PANDEMIC PERIOD IN RELATION TO THE INCIDENCE OF MACULAR DEGENERATION.....	637
Strahil Gazepov	637
Rozita Evnusheva	637
Tanja Pecanova.....	637
Emilija Simeonova Srebranova	637
DESCRIPTIVE STUDY OF NON-PROLIFERATIVE CORRELATED WITH PROLIFERATIVE DIABETIC RETINOPATHY IN CLINICAL HOSPITAL SHTIP	643
Strahil Gazepov	643
Doruntina Selimi Ademi.....	643
Eleonora Grozdanova	643
Biljana Gjorgieva.....	643
Toni Shekerinov	643
PROLONGED WORK IN KINDERGARTEN AND THE RISK OF HEARING PROBLEMS	649
Anna Andreeva.....	649
STUDY OF THE DURATION OF NIGHT AND AFTERNOON SLEEP IN PRE-SCHOOL AGE CHILDREN	657
Vanya Pavlova.....	657
Ruska Paskaleva	657
Violeta Ivanova.....	657
IMPACT OF RESPIRATORY GYMNASTICS ON POST-COVID PATIENTS.....	665
Lence Nikolovska	665

KINESITHERAPY AFTER SURGERY TREATMENT OF ANCLE FRACTURES	671
Steliyana Valeva.....	671
Nazife Bekir.....	671
PROPRIOCEPTIVE TRAINING IN THE COMPLEX FUNCTIONAL RECOVERY AFTER LATERAL ANKLE SPRAIN	677
Lyubomira Sazdova.....	677
THE POSSIBILITIES OF IMPACT OF PHYSIOTHERAPY IN PATIENTS WITH POST-COVID SYMPTOMS. (RE)START FOR MIND AND BODY	683
Kristiyan Stoychev	683
Frosina Petroska	683
APPLICATION OF INNOVATIVE TECHNOLOGIES IN KINESITHERAPY IN RECOVERY OF TRAUMATIC INJURIES OF THE KNEE JOINT	687
Nora Taneva-Georgieva	687
Ruska Paskaleva	687
EFFECT OF REHABILITATION AFTER VERTEBROPLASTY OF SPINE AT TH11, L2 LEVEL - A CLINICAL CASE REPORT	693
Violeta Ivanova.....	693
Ruska Paskaleva	693
Vanya Pavlova.....	693
RECOVERY OF POST COVID-19 SURVIVORS WITH THE METHODS OF SANATORIAL AND SPA TREATMENT	699
Mariyana Petrova.....	699
Krasimira Takucheva.....	699
Katya Mollova	699
IMPACT OF THE COVID 19 PANDEMIC ON THE NUMBER OF VISITORS IN KATLANOVSKA SPA	705
Evgenija Markovska	705
EVALUATION OF THE PROGNOSTIC ROLE AND CLINICAL RELEVANCE OF LABORATORY BIOMARKERS IN HOSPITALIZED PATIENTS WITH COVID-19.....	711
Desislava Arabadzhyska.....	711
Tanya Deneva	711
SIGNIFICANCE OF PRE-ANALYTICAL PHASE IN PATHOHISTOLOGICAL DIAGNOSTIC PROCESS – THE ROLE OF LABORATORY TECHNICIAN IN QUALITY ASSURANCE.....	717
Krasimira Dinkova	717
IMPLEMENTATION OF CHROMATOGRAPHY DATA SYSTEM IN A QUALITY CONTROL LABORATORY IN THE PHARMACEUTICAL INDUSTRY	723
Nikola Simonovski	723
Biljana Gjorgjeska	723
NEW ANTIMICROBIALS IN THE CURRENT PIPELINE ACTIVE AGAINST MULTIDRUG-RESISTANT BACTERIA	729
Rozalina Yordanova	729
Plamena Gateva	729
Nevena Nedeva.....	729
NUTRITIONAL HABITS AND PHYSICAL ACTIVITY OF STUDENTS IN A PRIMARY SCHOOL IN KONJIC	733
Nejra Čibo	733
Hana Omerović.....	733
Ema Pindžo.....	733
Zarema Obradović.....	733

EFFECTS OF PROTEIN SUPPLEMENTS ON LIVER ENZYMES LEVELS IN ATHLETES.....	743
Lejla Čano Dedić	743
Arzija Pašalić.....	743
Sabina Šegalo	743
Nafija Serdarević	743
Amna Vefić	743
EVALUATION OF TOPICAL PREPARATIONS OF MELOXICAM-A REVIEW.....	749
Elena Drakalska Sersemova	749
Bistra Angelovska.....	749
FORMULATION OF DIAZEPAM SUPPOSITORIES WITH HYDROPHILIC AND LIPOPHILIC BASES	755
Dijana Miceva.....	755
Bistra Angelovska.....	755
CATALASE ACTIVITY IN RAT BLOOD SERUM UNDER THE IMPACT OF IONIZED WATER SUPPLEMENTED WITH GLUTATHIONE AND VITAMIN C DURING HYPERTHERMIC STRESS	759
Majlinda Ademi.....	759
CORELATION BETWEEN COLAGEN INDUCED ARTHRITIS AND RF IN WHITE LABORATORY RAT	765
Mire Spasov	765
COMPARATIVE STUDY OF LACOSAMIDE, LAMOTRIGINE AND TOPIRAMATE TREATMENT ON PASSIVE LEARNING AND MEMORY IN NAÏVE RATS.....	771
Michaela Shishmanova-Doseva	771
MODELING A MASS SERVICE SYSTEM FOR COVID-19 VACCINES.....	777
Petya Stoyanova	777
PROPOSAL FOR THE CREATION OF CLINICAL-LABORATORY CONSTELLATIONS FOR COVID-19.....	783
Ivelina Dobрева	783
DIFFERENCES IN PERCEPTED STRESS AMONG HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (IN RELATION TO THE WORKPLACE)	789
Hana Omerović.....	789
Nejra Čibo	789
Ema Gojak Pindžo	789
Zarema Obradović	789
Đemil Omerović	789
Edina Tanović.....	789
Vedina Čordalija.....	789
Emina Rovčanin	789
ANALYSIS OF SOFTWARE SOLUTIONS FOR THE MANIPULATION AND PROCESSING OF IMAGING NEUROLOGICAL NUCLEAR MEDICINE STUDIES	799
Aleksandra Kerleta- Hadziahmetovic	799
Miran Hadziahmetovic	799
Marko Tvrtković.....	799
Selma Agić- Bilalagić.....	799
Šejla Cerić	799
Amila Bašić	799
Ajla Arnautović- Halimić	799
Sadžida Begović- Hadžimuratović	799
Amela Begić	799

DOCUMENTATION AS AN INTEGRAL PART OF QUALITY ASSURANCE IN THE PHARMACEUTICAL INDUSTRY.....	807
Nikola Simonovski	807
Biljana Gjorgjeska	807
INTELLECTUAL PROPERTY RIGHTS AND MISLEADING ADVERTISING OF DRUGS AND COSMETIC PRODUCTS IN THE REPUBLIC OF NORTH MACEDONIA	813
Biljana Nestorovska-Gjoshevska.....	813
Marija Glavash-Dodov	813
Aleksandra Grozdanova	813
Zoran Sterjev	813
Katerina Anchevska-Netkovska	813
THE ORGANIZATION OF THE WORK PROCESS AS A PART OF THE MANAGER PHARMACIST'S FUNCTIONS	817
Michaela Shishmanova-Doseva	817
Maria Semerdjieva.....	817
INEQUALITIES IN IVD MARKET IN EU COUNTRIES	823
Boyan Ignatov.....	823
IMPACT OF ONLINE-BASED TRAINING ON PHYSICAL AND MENTAL HEALTH	831
Anushka Uzunova.....	831
Petya Krumova	831
Ana Nikolova.....	831
EDUCATIONAL EFFICACY AND SELF-EFFICACY USING CLINICAL SIMULATIONS IN MEDICAL EDUCATION	837
Mariana Bacheva	837
Rosica Doynovska	837
NEEDS ANALYSIS OF FIRST YEAR MEDICAL BACHELORS' OPINIONS OF ESP COURSE DESIGN	845
Ivaylo Dagnev.....	845

ASSOCIATION OF THE TREATMENT WITH 5 ALPHA-REDUCTASE INHIBITORS WITH THE PSYCHOLOGICAL WELL-BEING OF PATIENTS WITH BENIGN PROSTATE HYPERPLASIA

Maja Sofronievska Glavinov

University Clinic for Surgical Diseases "St. Naum Ohridski", Skopje, North Macedonia,
maja.sofronievska@ugd.edu.mk

Abstract: Benign prostatic hyperplasia is defined as a disorder, which has different ways of treatment depending on the symptomatology, the response to drug therapy, and the occurrence of complications. Pharmacological treatment of benign prostatic hyperplasia involves the use of mainly two groups of drugs: alpha 1 blockers and 5 alpha-reductase inhibitors (5ARIs). Side effects commonly occur during treatment with 5ARIs such as erectile dysfunction, decreased libido, and deterioration of psychological well-being. This paper aims to determine the association between DHEAS deficiency and the occurrence of side effects of 5ARI therapy that relate to the psychological well-being of patients with BPH. The analysis included 250 patients with benign prostatic hyperplasia (BPH), of whom 130 were treated with an alpha 1 blocker, while 120 patients were treated with a combination of tamsulosin and 5ARIs. The evaluation was conducted through questionnaires: IPSS (International Prostate Scoring System) to quantify BPH symptoms and PhQ-9 questionnaire for self-evaluation of depressive symptoms. The results showed that impaired psychological well-being occurred in 26 patients (22.5%) in the study group after 6- and 12-month therapy, which was statistically significant in this group ($p < 0.05$). In these patients, there were also initially reduced serum values of dehydroepiandrosterone sulfate (DHEAS) ($p < 0.05$). In this analysis, we concluded that the occurrence of impaired psychological well-being in patients treated with 5ARIs correlates with initially lower serum values of DHEAS before the start of therapy, which should be taken into account when using these medications.

Keywords: benign prostatic hyperplasia, side effects, psychological well-being

1. INTRODUCTION

Comparative knowledge and definition of benign prostatic hyperplasia is a disorder of the division of stem cells in the prostate where the "sleeping" stem cells are awakened and cells capable of division are created, increasing their number, and thus causing an increase in the volume of the prostate. When proliferating cells mature through the process of terminal differentiation, they have a limited lifespan before programmed cell death occurs (Bushman, 2009). Alpha-adrenergic blockers and 5 α -reductase inhibitors and their combination are the "gold standard" in the medical treatment of BPH (EAU Guidelines, 2022). Inhibition of 5 α -reductase results in almost complete and consistent suppression of the conversion of serum testosterone and dihydrotestosterone and more than 85% of men treated, results in a reduction of the serum level of more than 90% within 4 weeks (Roehborn et al., 2010).

The view of the nature of BPH has recently broadened to include comorbidities and treatment effects. From the moment of starting the therapy with dutasteride, research is directed toward the occurrence of side effects which confirmed that the negative effects of the drugs used for the treatment of BPH and surgical procedures are risk factors for the development of erectile dysfunction and depressive state. (Roehborn et al., 2002, McConnell et al., 2003).

The mood disturbance induced by 5ARIs may be attributed to their inhibitory effect on androgen and steroid 5 α -reduction in the brain. Since dutasteride is a potent dual inhibitor, it also has inhibitory effects on the brain-predominant 5ARI type 1 (Harris, 1992). Mechanisms of occurrence of these mood disorders that depend on neurosteroid interactions and synthesis have been elucidated and well-known through the biosynthesis and conversion of steroids mediated by 5 alpha reductases. Neurosteroids can be formed from their parent steroid hormones directly in the brain or synthesized in peripheral tissues (Reddy, 2010). Although steroid precursors of neurosteroids are mainly synthesized in the gonads, adrenal gland, and fetoplacental unit their conversion occurs in peripheral tissues such as reproductive endocrine tissues, liver, and skin which are rich in both types of 5 alpha-reductase required for their conversion. (Do Rego et al., 2009). Steroid precursors also readily enter the brain, so precursor bases synthesized in the periphery are readily available for the local biosynthesis of neurosteroids. Five alpha-reductase activity has been identified in both neurons and glial cells in the brain (Melcangi et al., 2013).

The lack of neurosteroids has a key role in the occurrence of depression. Animal studies have shown that fluoxetine, a selective serotonin inhibitor and widely used antidepressant, increases allopregnanolone levels in the brain (Uzunova et al., 1996). Testosterone in the brain is transformed into estradiol by the enzyme aromatase and into dihydrotestosterone (DHT) by 5 α -reductase, after which it binds to androgen receptors. The complete absence of an

association between circulating estradiol and mood outcomes does not rule out the hypothesis that testosterone's influence on mood is mediated by estradiol aromatization (McEwen, 1981). The sulfurized neurosteroids pregnenolone sulfate (PS) and DHEAS, as well as DHEA, have clear antidepressant effects (Reddy et al., 1998). Dehydroepiandrosterone and its precursor DHEAS have been widely investigated as novel antidepressants. Their importance as neurosteroids is all the greater because their synthesis and further action in brain tissue do not depend on the activity of 5 α -reductase (Wolkowitz et al., 1999).

This paper aims to determine the association between DHEAS deficiency and the occurrence of side effects of 5ARI therapy that relate to the psychological well-being of patients with BPH.

2. MATERIAL AND METHODS

In this prospective study, we evaluated the adverse effects of the 5-ARIs (dutasteride) in patients diagnosed with benign prostatic hyperplasia (BPH) by following the ethical standards of the Helsinki Declaration revised in Seoul in 2008. Patients included in this study signed a written informed consent to participate and the study was approved by the ethics committee at the institution where it was conducted.


A total of 250 patients met the inclusion criteria of the study, age from 40 to 70 years, prostate volume more than 40ml, total PSA serum levels less than 4ng/ml and first visit to a urologist due to different degrees of lower urinary tract symptoms (LUTS). Quantification of LUTS was done with the International Prostate Symptom Score (IPSS) questionnaire. Exclusion criteria were dementia, deafness, medical history of mental disorders, vascular disease, myocardial infarction, diabetes mellitus, and prostate cancer. Patients were randomized into two groups depending on the BPH therapy they were prescribed in a control group (CG) of patients treated with alpha tamsulosin (n=130/250) and an investigated group (IG) that were treated with a combination of tamsulosin and dutasteride (n=120/250).

At the beginning of the study, all patients included had normal psychological status without signs of depression, measured by the PhQ-9 self-evaluation questionnaire. The PHQ-9 (Patient health questionnaire-9) questionnaire is a standardized and validated self-assessment tool that consists of nine short and simple questions that are built on the criteria for depression identified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Determination of mood disorder in all patients was done at the beginning of the study and two control points after 6 and 12 months of continuous drug treatment. All patients who had mood swings and clinically significant mood swings were excluded at the start of the study.

3. RESULTS

The obtained values from the studied parameters were entered into the database of the program Statistics 7 and processed with it. Evaluation of the obtained data provided insight into the impact of BPH therapy on the mental state of patients. The depression self-assessment questionnaire (PHQ-9) presented non-significantly different sums between the two groups of patients before therapy (p=0.17) (graph 1a) and significantly different after 6 months (p=0.011) (graph 1b) and after 12 months of therapy (p=0.046) (graph 1c), as a result of significantly higher scores for the questionnaire obtained in patients on dual therapy.

Graph 1. Box presentation of PhQ-9 in both groups at 0-month (a), 6th month (b), and 12th month (c)



The mean PHQ-9 score was 2.14 ± 3.6 in the investigated group of patients treated with combination therapy, 0.38 ± 0.7 in the group treated only with an alpha1 blocker after 6 months from the start of therapy, and 1.99 ± 3.7 and 0.23 ± 0.5 , consistently in the group of patients treated with monotherapy and combination therapy (table 1).


Table 1. Comparative analysis of the control group (CG) and investigated group (IG) to PHQ-9 score (Z - Mann-Whitney)

Group	PHQ-9		p value
	(mean \pm SD)	median (IQR)	
0 - month			
CG	1.35 \pm 1.4	1 (0 – 3)	Z=1.38 p=0.17 ns
IG	1.52 \pm 1.3	1 (0 – 2.5)	
6th month			
CG	0.38 \pm 0.7	0 (0 – 1)	Z=2.52 p=0.011 sig
IG	2.14 \pm 3.6	0 (0 – 1)	
12th month			
CG	0.23 \pm 0.5	0	Z=1.82 p=0.046sig
IG	1.99 \pm 3.7	0 (0 – 1)	

From the analysis, it is evident that after 6 and 12 months of therapy for BPH 26 patients treated with combination therapy expressed mood disorders of varying degrees. This indicates that the type of drug therapy significantly affects the mood disorder of patients.

According to the results, during the treatment period, depressive symptoms were not registered in any patient from CG, while in IG 21 (17.5%) patients manifested weak mood deviations, and 5 (4.2%) patients had mild depression (graph 2).

Graph 2. Percentage presentation of patients with different degrees of mood disorder in two patients groups in the control points



Regarding patients' age, mood disorders were most common in patients aged between 51 and 60 years (77.78%), in one patient under the age of 51 (3.7%), and 5 (18.52%) patients aged between 61 and 70 years (table 2).

Table.2 Number of patients with MD concerning the age of the patients

Age	MD n (%)
45-50	1 (3.7)
51-60	21 (77.78)
61-70	5 (18.52)
(mean+/-SD) (min-max)	(61.52+/-5.2) (49-69)


The correlation between the PHQ-9 scale and serum DHEAS level after 6 and after 12 months of therapy in CG ($p=0.86$ and $p=0.82$ respectively) did not show significance. The correlation between the PHQ-9 scale and the serum level of DHEAS showed significance ($p<0.0001$) in the group treated with combination therapy, which is shown in table 3.

Table 3. Correlation between PHQ-9 and serum DHEAS values in both groups at both control points

DHEAS & PHQ-9	CG		IG	
	Spearman R	p-level	Spearman R	p-level
6 th month	0.016	0.86 ns	-0.573	0.000 sig
12 th month	0.019	0.82 ns	-0.649	0.000 sig

In the investigated group that was treated with combination therapy, the correlation was significant at both time points ($p<0.0001$), with Spearman's coefficient values of $R = -0.573$ and $R = -0.649$, respectively after 6 and 12 months from the start of therapy, which indicate a negative, indirect correlation (graph 3).

Graph 3. Negative, the indirect correlation between PHQ-9 and DHEAS after 6 (a) and 12 (b) months in the investigated group (Spearman rank)



As the serum DHEAS level decreased, the PhQ-9 sum increased and vice versa. Patients treated with combination therapy for BPH that has had initially lower serum DHEAS values had a worse PHQ-9 depression questionnaire score and vice versa.

4. DISCUSSION

Based on the results of the PHQ-9 questionnaire, patients from the control group had no symptoms of depression or disturbance of psychological well-being during the entire follow-up period after the beginning of therapy.

Disturbance of psychological well-being was registered in 26 patients from the study group, of which 21 (77.8%) had a mild mood disorder, and 5 (18.5%) had mild depression after 6 and 12 months of medical therapy for BPH. All 26 patients who at the beginning of the research were in a completely normal psychological state, after the medical treatment with 5ARI showed a certain degree of disturbed mood and depression. At the same time, these patients showed significantly lower initial values of DHEAS. Patients on combination medical therapy for BPH with lower serum DHEAS values (below 80 µg/dL) exhibited varying degrees of depression.

The results of this analysis pointed towards finding that patients who have low serum DHEAS values and are susceptible to the action of dutasteride (5ARIs) are more prone to deterioration of their psychological well-being than patients treated with tamsulosin alone.

Serum DHEAS levels decrease with aging and reference values are adjusted to the age. However, in some individuals, this drop in the level of DHEAS is greater than expected and could precipitate conditions related to its deficiency. Dehydroepiandrosterone sulfate is the only steroid in the human body on which 5 α -reductases do not influence the processes of bioconversion. In conditions where 5 α -reductases are inhibited by 5ARIs due to the treatment of BPH, the biosynthesis of these neurosteroids in the brain remains impaired. On the other hand, DHEAS is been proven to have direct antidepressant and cognitive properties and is also known as a neurosteroid that can increase feelings of well-being and is useful in ameliorating atypical depressive disorders (Stárka et al., 2015).

The impaired bioconversion of steroids due to the inhibition of 5 α - reductase on the one hand and the low serum values of DHEAS, as a direct neurosteroid, contributes to the manifestation of depressive symptoms and impaired psychological well-being of patients.

The most relevant finding on the association between BPH pharmacotherapy and the occurrence of a depressive state is a study that confirmed that the use of 5-ARIs was associated with a 1.52-fold higher prevalence of depressive symptoms (Pietrzyk et al., 2015). However, the authors do not explain the reason for the occurrence of depression in these patients, which is achieved in our analysis.

It is important to stress the role of 5 α -reductase in the biotransformation of steroids into neurosteroids as a very important biological process in establishing good mental status and psychological well-being. By inhibiting 5 α -reductase, 5ARIs not only inhibit the conversion of testosterone to dihydrotestosterone but also affect the reduced synthesis of neurosteroids. This results in varying degrees of mood disorders and depression (Rahimi-Ardabili, 2006). We find this important and suggest the exogenous substitution of DHEA in patients with low serum levels (below 80 µg/dL) to maintain psychological well-being while treated with 5ARIs due to BPH.

The analysis of the results in this paper explains the reason for the occurrence of mood disorders associated with the use of 5ARIs by determining the association with serum levels of DHEAS. Its importance is to clarification of the potential negative side effects of inhibitors that target 5 alpha reductases for the treatment of benign hyperplasia of the prostate.

5. CONCLUSION

Low DHEAS values in conditions of inhibited activity of 5 α -reductases and disturbed biosynthesis of other neurosteroids lead to varying degrees of mood disorders. When determining the duration of pharmacological treatment of patients with BPH, it is necessary to monitor the serum values of DHEAS, considering that this study proved that initially low values are the cause of mood disorders in patients with BPH who are on pharmacotherapy with 5ARIs.

REFERENCES

- Bushman, W. (2009). Etiology, epidemiology, and natural history of benign prostatic hyperplasia. *The Urologic clinics of North America*, 36(4), 403–v.
- Celec, P., Ostatníková, D., & Hodosy, J. (2015). On the effects of testosterone on brain behavioral functions. *Frontiers in neuroscience*, 9, 12.
- Connolly, S. S., & Fitzpatrick, J. M. (2007). Medical treatment of benign prostatic hyperplasia. *Postgraduate medical journal*, 83(976), 73–78.
- Do Rego, J. L., Seong, J. Y., Burel, D., Leprince, J., Luu-The, V., Tsutsui, K., Tonon, M. C., Pelletier, G., & Vaudry, H. (2009). Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. *Frontiers in neuroendocrinology*, 30(3), 259–301.
- Hagberg, K. W., Divan, H. A., Nickel, J. C., & Jick, S. S. (2017). Risk of Incident Antidepressant-Treated Depression Associated with Use of 5 α -Reductase Inhibitors Compared with Use of α -Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink. *Pharmacotherapy*, 37(5), 517–527. <https://doi.org/10.1002/phar.1925>

- Haque, N., Masumori, N., Sakamoto, S., Ye, Z., Yoon, S. J., Kuo, H. C., Brotherton, B., Wilson, T., Muganurmath, C., McLaughlin, M., & Manyak, M. (2018). The superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men. *International journal of urology: official journal of the Japanese Urological Association*, 25(11), 944–951.
- Li, K., Liang, S., Shi, Y., Zhou, Y., Xie, L., Feng, J., Chen, Z., Li, Q., & Gan, Z. (2021). The Relationships of Dehydroepiandrosterone Sulfate, Erectile Function, and General Psychological Health. *Sexual medicine*, 9(4), 100386.
- Melcangi, R. C., Caruso, D., Abbiati, F., Giatti, S., Calabrese, D., Piazza, F., & Cavaletti, G. (2013). Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. *The journal of sexual medicine*, 10(10), 2598–2603.
- Motofei, I. G., Rowland, D. L., Baconi, D. L., Tampa, M., Sârbu, M. I., Păunică, S., Constantin, V. D., Bălălaşu, C., Păunică, I., & Georgescu, S. R. (2018). Androgenetic alopecia; drug safety and therapeutic strategies. *Expert opinion on drug safety*, 17(4), 407–412.
- Pietrzyk, B., Olszanecka-Glinianowicz, M., Owczarek, A., Gabryelewicz, T., Almgren-Rachtan, A., Praisner, A., & Chudek, J. (2015). Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. *International urology and nephrology*, 47(3), 431–440. <https://doi.org/10.1007/s11255-015-0920-5>
- Rahimi-Ardabili, B., Pourandarjani, R., Habibollahi, P., & Mualeki, A. (2006). Finasteride induced depression: a prospective study. *BMC clinical pharmacology*, 6, 7.
- Reddy D. S. (2010). Neurosteroids: endogenous role in the human brain and therapeutic potentials. *Progress in brain research*, 186, 113–137.
- Samaras, N., Samaras, D., Frangos, E., Forster, A., & Philippe, J. (2013). A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?. *Rejuvenation research*, 16(4), 285–294.
- Stárka, L., Dušková, M., & Hill, M. (2015). Dehydroepiandrosterone: a neuroactive steroid. *The Journal of steroid biochemistry and molecular biology*, 145, 254–260. <https://doi.org/10.1016/j.jsbmb.2014.03.008>
- Šrámková, M., Dušková, M., Hill, M., Bičíková, M., Řířpová, D., Mohr, P., & Stárka, L. (2017). The role of steroids in the prediction of affective disorders in adult men. *Steroids*, 121, 47–53.
- Walther, A., Mahler, F., Debelak, R., & Ehlert, U. (2017). Psychobiological Protective Factors Modifying the Association Between Age and Sexual Health in Men: Findings From the Men's Health 40+ Study. *American journal of men's health*, 11(3), 737–747.
- Zaric, M., Drakulic, D., Dragic, M., Gusevac Stojanovic, I., Mitrovic, N., Grkovic, I., & Martinovic, J. (2019). Molecular Alterations and Effects of Acute Dehydroepiandrosterone Treatment Following Brief Bilateral Common Carotid Artery Occlusion: Relevance to Transient Ischemic Attack. *Neuroscience*, 410, 128–139.